EMBRACE: Phase 3/4, Randomized, 52‐Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Lupus Erythematosus ◽

African Ancestry ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3 ◽

Black African

Faculty Opinions recommendation of Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8909956.9465054 ◽

2011 ◽

Author(s):

David Kluth ◽

Neeraj Dhaun

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1195 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 141.1-141 ◽

Cited By ~ 6

Author(s):

D. Isenberg ◽

J. Merrill ◽

R. Hoffman ◽

M. Linnik ◽

M. Morgan-Cox ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Yearbook of Medicine ◽

10.1016/j.ymed.2011.09.006 ◽

2011 ◽

Vol 2011 ◽

pp. 18-19

Author(s):

R.S. Panush

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

AB0412 Exploratory Results from The Bliss and Illuminate Trials Support The Design of The CHABLIS-SC1 Trial, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.1091 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 1047.2-1047 ◽

Cited By ~ 2

Author(s):

J.T. Merrill ◽

V. Strand ◽

C. Hislop ◽

M. Gangal ◽

R.S. Martin ◽

...

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(10)61354-2 ◽

2011 ◽

Vol 377 (9767) ◽

pp. 721-731 ◽

Cited By ~ 1023

Author(s):

Sandra V Navarra ◽

Renato M Guzmán ◽

Alberto E Gallacher ◽

Stephen Hall ◽

Roger A Levy ◽

...

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial

Modern Rheumatology ◽

10.1080/14397595.2018.1480915 ◽

2018 ◽

Vol 29 (3) ◽

pp. 452-460 ◽

Cited By ~ 1

Author(s):

Yoshiya Tanaka ◽

Damon Bass ◽

Myron Chu ◽

Sally Egginton ◽

Beulah Ji ◽

...

Keyword(s):

Lupus Erythematosus ◽

Subgroup Analysis ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Case Medical Research ◽

10.31525/ct1-nct04058028 ◽

2019 ◽

Author(s):

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Faculty Opinions recommendation of Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737043169.793576809 ◽

2020 ◽

Author(s):

Tak Mao Chan ◽

Susan Yung

Keyword(s):

Lupus Erythematosus ◽

Type I Interferon ◽

Type I ◽

Systemic Lupus ◽

Phase 3 ◽

Randomised Controlled

PMS43 Efficacy And Safety Of Pharmaceutical Treatments For Systemic Lupus Erythematosus (SLE): A Systematic Literature Review (SLR) Of Randomized Controlled Trials (RCTs)

Value in Health ◽

10.1016/j.jval.2020.08.1174 ◽

2020 ◽

Vol 23 ◽

pp. S600

Author(s):

D. Willems ◽

L. Sladkeviciute ◽

B. Szegvari ◽

A. Mevius ◽

S. Müller

Keyword(s):

Literature Review ◽

Randomized Controlled Trials ◽

Systematic Literature Review ◽

Lupus Erythematosus ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Randomized Controlled